Results 41 to 50 of about 643,840 (294)

When Your Doctor “Gets It” and “Gets You”: The Critical Role of Competence and Warmth in the Patient–Provider Interaction

Frontiers in Psychiatry, 2019
Background: Research demonstrates that the placebo effect can influence the effectiveness of medical treatments and accounts for a significant proportion of healing in many conditions. However, providers may differ in the degree to which they consciously
Lauren C. Howe, Kari A. Leibowitz, Alia J. Crum   +2 more
doaj   +1 more source

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. [PDF]

, 2017
Lessons learnedThe safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group.The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients ...
Bendell, Johanna, Benson, Al B, Hecht, J Randolph, Verma, Udit, Vyushkov, Dmitry, Yang, Yingsi   +5 more
core   +1 more source

N-acetyl-cysteine, a drug that enhances the endogenous activation of group-II metabotropic glutamate receptors, inhibits nociceptive transmission in humans. [PDF]

, 2015
Emerging research seeking novel analgesic drugs focuses on agents targeting group-II metabotropic glutamate receptors (mGlu2 and mGlu3 receptors). N-Acetylcysteine (NAC) enhances the endogenous activation of mGlu2/3 receptors by activating the glial ...
BATTAGLIA, Giuseppe, CRUCCU, Giorgio, DI STEFANO, GIULIA, E. Pasquale, LATTANZI, Roberta, NICOLETTI, Ferdinando, PIROSO, SERENA, S. Notartomaso, TRUINI, ANDREA   +8 more
core   +1 more source

Twenty years after ‘Listening to Prozac but hearing placebo’. Do we hear placebo even louder?

Health Psychology Report, 2019
An active placebo is a substance that produces side effects similar to an active ingredient while not producing the same intended therapeutic effect. The aim of this study is to review the literature on the hypothesis of the active placebo response as a ...
Wojciech Oronowicz-Jaśkowiak, Przemysław Bąbel   +1 more
doaj   +1 more source

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials. [PDF]

PLoS Biology, 2016
Placebo response in the clinical trial setting is poorly understood and alleged to be driven by statistical confounds, and its biological underpinnings are questioned.
Pascal Tétreault, Ali Mansour, Etienne Vachon-Presseau, Thomas J Schnitzer, A Vania Apkarian, Marwan N Baliki   +5 more
doaj   +1 more source

Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. [PDF]

, 2017
A single dose of the apolipoprotein (apo)A-I mimetic peptide D-4F rendered high-density lipoprotein (HDL) less inflammatory, motivating the first multiple-dose study. We aimed to assess safety/tolerability, pharmacokinetics, and pharmacodynamics of daily,
Bloedon, LeAnne T., Duffy, Danielle, Dunbar, Richard L., Fogelman, Alan M., Movva, Rajesh, Navab, Mohamad, Norris, Robert B., Rader, Daniel J.   +7 more
core   +2 more sources

Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.
Tuhin Virmani, Lakshmi Pillai, Reid D. Landes, Aliyah Glover, Shannon Doerhoff, Jennifer Kleiner, Mitesh Lotia, Rohit Dhall, Edgar Garcia‐Rill   +8 more
wiley   +1 more source

Racial Differences in the Effect of Granulocyte Macrophage Colony-Stimulating Factor on Improved Walking Distance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. [PDF]

, 2019
Background The effects of race on response to medical therapy in people with peripheral artery disease ( PAD ) are unknown. Methods and Results In the PROPEL (Progenitor Cell Release Plus Exercise to Improve Functional Performance in PAD) Trial, PAD ...
Criqui, Michael H, Domanchuk, Kathryn, Ferrucci, Luigi, Guralnik, Jack M, Kibbe, Melina R, Li, Lingyu, McDermott, Mary M, Polonsky, Tamar S, Stein, James, Taylor, Doris A, Tian, Lu, Zhao, Lihui   +11 more
core   +1 more source